Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Ipsen: Clinical Trials & FDA Approval Profile

Ipsen (Global / Institutional) sponsors 36 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 19 active protocols (7 recruiting now), 13 completed protocols, and 5 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)11.1%
Median Closed Enrollment vs National (145 pts)80 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Ipsen
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)36
Active Pipeline (Recruiting Now)19 (7)
Completed vs Stopped Early13 / 4 (11.1%)
Median Closed Actual Enrollment80 participants
Physical Hospital Site Disclosure99.8% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals5 (3 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Ipsen
Hospital Research SiteLocationShared Protocols
Hospital Universitario Vall d'HebronBarcelona7
Hospital Universitario La PazMadrid6
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CT5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Ipsen
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07387549A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisPhase IIIRECRUITING
NCT06016842A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisPhase IIIRECRUITING
NCT06937931A Study of IPN10200 for the Treatment of Cervical Dystonia in AdultsPhase IIRECRUITING
NCT04526665Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Phase IIIACTIVE NOT RECRUITING
NCT05627362A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.Phase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Ipsen Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI